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Abstract
Introduction:  Bevacizumab is a monoclonal antibody that inhibits the action of vascular
endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of
oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side
effects due to bevacizumab are hypertension and increased risk of bleeding. Bowel perforation has
also been reported. Periodontal disease in patients on bevacizumab therapy has not been reported
before.
Case Presentation: We report a case of a forty-three year old woman who developed
periodontitis whilst receiving bevacizumab for lung cancer. The periodontal disease remained stable
on discontinuation of the drug.
Conclusion: Further investigations are needed to determine the mechanism for bevacizumab-
induced periodontal disease.
Introduction
Bevacizumab is a monoclonal antibody that inhibits the
action of vascular endothelial growth factor (VEGF)
thereby acting as an angiogenesis inhibitor and prevent-
ing the formation of new blood vessels, including those
that surround and supply cancer cells. As a result, supply
of oxygen and nutrients to tissues is impaired and tumour
cell growth is reduced. Cancerous tumours may become
slower growing or even smaller.
It is this property that has found non-oncological uses for
bevacizumab as its anti-angiogenesis effect has been use-
ful in the treatment of proliferative (neovascular) eye dis-
eases, particularly age-related macular degeneration [1-4].
Reported side effects due to bevacizumab are hyperten-
sion and increased risk of bleeding. Bowel perforation has
also been reported [5-8].
Periodontal diseases range from simple gum inflamma-
tion to serious disease that results in major damage to the
soft tissue and bone that support the teeth. Risk factors for
the development of periodontal disease are smoking, hor-
monal changes in women, poor nutrition resulting in
deficiencies in calcium and certain vitamins (especially
vitamins B and C), diabetes, gingivitis, stress, immuno-
suppressive illnesses, genetic susceptibility and certain
medications (including chemotherapy drugs and those
that reduce the production of saliva such as antidepres-
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sants, antihistamines, antiepileptics, and calcium channel
blockers). [9,10].
Previous studies have shown increased levels of VEGF in
gingival and gingival crevicular fluid in patients with per-
iodontitis, in keeping with an inflammatory process
induced by periodontopathogens, with neovascularisa-
tion causing swelling and oedema [11,12]. It is possible
that VEGF levels are high in an attempt to stimulate ang-
iogenesis and facilitate healing. Regeneration of perio-
dontal structures lost during periodontal disease is
regulated by, among other things, interactions between
cells and growth factors.
Case Presentation
A 43 year old lady presented in 2005 with wheeze, short-
ness of breath and pain in the right back. She had no other
symptoms of note and was an ex-smoker. The patient had
had an ovarian cystectomy in 2004 which was compli-
cated by fistula formation requiring several laparotomies.
At bronchoscopy, obstruction by a large right middle lobe
tumour was noted and biopsy confirmed an adenocarci-
noma. Subsequent PET-CT scanning revealed extensive
soft tissue abnormalities in the right paravertebral region
posteriorly and lymphadenopathy in the subcarinal, con-
tralateral and pretracheal regions. The final staging was
T2N3M0 (IIIB).
The patient was enrolled in the AVAiL trial (AVAstin In
Lung cancer – Trial No. BO17704) – a study in which the
primary objective is to evaluate safety and efficacy of two
doses of bevacizumab in combination with gemcitabine
and cisplatin and determine the optimal dose of bevacizu-
mab. The trial is a randomised, double-blind, multicentre,
2-stage, phase III study of bevacizumab and gemcitabine/
cisplatin versus placebo and gemcitabine/cisplatin in
patients with advanced or recurrent non-small cell lung
carcinoma who have not received prior chemotherapy.
The patient was randomised to receive gemcitabine/cispl-
atin and bevacizumab on the maintenance arm.
Five cycles of treatment (carboplatin was substituted for
cisplatin at cycle 3 due to toxicity) were completed in
March 2006 with partial response. At cycle 6 (eighteen
weeks into treatment), marked gum recession was noted
(fig 1). The patient was then unblinded and found to be
on the continuation arm of bevacizumab. Treatment was
continued with no interventions and the patient
remained entirely asymptomatic.
In September 2006 (ten months after commencing treat-
ment), the patient was noted to have worsening periodon-
tal disease (fig 2). She had completed 18 cycles of
bevacizumab at this stage. The patient completed treat-
ment in December 2006 and the periodontal disease has
since remained stable.
This case is, to the best of our knowledge, the first reported
of a patient developing periodontal disease whilst receiv-
ing bevacizumab. Although it would be difficult to
exclude all other risk factors in this patient, the onset of
periodontal disease on commencement of bevacizumab
and the fact that the disease remained stable on discontin-
uation of the drug points to this as the cause.
Conclusion
In this case, one might expect low plasma levels of VEGF
with the use of bevacizumab. It is possible that, as an ang-
iogenesis inhibitor, bevacizumab prevents the formation
of new blood vessels, resulting in a lack of supply of oxy-
gen and nutrients to the tissues. This may result in ischae-
Worsening periodontal disease at cycle 18 of bevacizumab  (10 months into treatment) Figure 2
Worsening periodontal disease at cycle 18 of bevacizumab 
(10 months into treatment).
Periodontal disease noted at cycle 6 of bevacizumab (18  weeks into treatment) Figure 1
Periodontal disease noted at cycle 6 of bevacizumab (18 
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mia and necrosis (consequently inhibiting reversal of the
process and impairing wound healing). Further investiga-
tions are therefore needed to determine the mechanism
for bevacizumab-induced periodontal disease.
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